Mechanical and durability properties of concretes containing recycled lime powder and recycled aggregates

According to a recent report by the European Commission, within the European Union, the construction and demolition wastes come to at least 450 million tons per year. Roughly 75% of the waste is disposed to landfill, despite its major recycling potential. The bulk constituents of demolition debris are concrete (50-55%) and masonry (30-40%) with only small percentages of other materials such as metals, glass and timber. In Cyprus, at present, recycling of waste materials is practically inexistent and almost the entire demolition waste products are disposed in landfill sites, with all possible economic, technical and environmental impacts. This research paper presents the evaluation and the effective reuse of waste construction materials, such as recycled lime powder (RLP) and recycled concrete aggregates (RCA), disposed to landfill sites in Cyprus, due to the lack of a lucid recycling policy and knowledge. Results show that both RLP and RCA have the potential to produce good quality and robust concrete mixtures both in terms of mechanical and durability performance. © 2013 Elsevier B.V. All rights reserved.

Industry perceptions of barriers to commercialization of regenerative medicine products in the UK.

AIMS: Regenerative medicine is an emerging field with the potential to provide widespread improvement in healthcare and patient wellbeing via the delivery of therapies that can restore, regenerate or repair damaged tissue. As an industry, it could significantly contribute to economic growth if products are successfully commercialized. However, to date, relatively few products have reached the market owing to a variety of barriers, including a lack of funding and regulatory hurdles. The present study analyzes industry perceptions of the barriers to commercialization that currently impede the success of the regenerative medicine industry in the UK. MATERIALS & METHODS: The analysis is based on 20 interviews with leading industrialists in the field. RESULTS: The study revealed that scientific research in regenerative medicine is thriving in the UK. Unfortunately, lack of access to capital, regulatory hurdles, lack of clinical evidence leading to problems with reimbursement, as well as the culture of the NHS do not provide a good environment for the commercialization of regenerative medicine products. CONCLUSION: Policy interventions, including increased translational government funding, a change in NHS and NICE organization and policies, and regulatory clarity, would likely improve the general outcomes for the regenerative medicine industry in the UK.